Dosage and protocol evidence
Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.
A 5 mg vial at a measured 5 mL final volume yields 1 mg/mL and 100 mcg per spray; 10 mL yields 0.5 mg/mL and 50 mcg per spray
This is concentration and actuator arithmetic, not a universal dose. Pump output, vehicle, priming, stability and the exact formulation must be independently established.
View sourceReported protocols ranged from single 0.25-1.2 mg exposures to a condition-specific 6 mg daily, 10-day post-stroke course
These distinct studies used different populations and formulations. Their quantities should be read individually rather than combined into one schedule.
View sourceEvidence summary
A synthetic ACTH fragment analogue studied mainly in Russian-language and intranasal contexts. Evidence does not map cleanly to a reconstituted injectable vial.
Protocol basis
This page reports the formulation mismatch as part of the protocol: published intranasal work is not converted into injectable quantities.
What remains uncertain
Independent replication, route-specific bioavailability, long-term safety and equivalence to research products remain uncertain.